Atezolizumab combined with R-GemOx shows favorable safety and efficacy in relapsed/refractory DLBCL, especially in transformed FL cases. The study reported a 59% overall response rate and a 33% ...

A new metabolic mechanism describes how tumors disable “gatekeeper” cells to prevent immune response to cancer.

Stratified analysis of mesothelioma mortality: A 21-year atlas of trends and demographic shifts in the United States. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This ...

Researchers have developed a new strain of vaccinia virus, which can replicate in tumor cells while maintaining increased immunogenicity. Specifically, it can to induce so-called immunogenic cell ...

Mayo Clinic researchers have developed a new method to identify which proteins are most likely to trigger an immune response ...